Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple s

Main measures

• Primary endpoint is the cumulative number of new T2-lesions on a brain MRI scan at study end compared to baseline in the Polyphenon E vs. placebo group.

  MRI lesions

• Results

  Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial.

  Neurol Neuroimmunol Neuroinflamm · 2021

1. Oct 2026In scope changed from true to false

1. Started

   Mar 2007